Ładuje się......
Assessing the clinical benefit of NMP22 in the surveillance of patients with non–muscle-invasive bladder cancer and negative cytology: a decision-curve analysis
BACKGROUND: Several studies have shown that abnormal levels of nuclear matrix protein 22 (NMP22) are associated with bladder cancer, leading to NMP22 being approved as a urinary biomarker by the FDA. Nonetheless, the clinical significance of NMP22 remains unclear. OBJECTIVE: To use decision analysis...
Zapisane w:
| Główni autorzy: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
2011
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3334293/ https://ncbi.nlm.nih.gov/pubmed/21692050 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25903 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|